Gene therapy to terminate tachyarrhythmias

References

• Dan GA, Martinez-Rubio A, Agewall S, et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5):731–2an.
   PubMed Web of Science ®Google Scholar
• Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133(14):e506–74.
   PubMed Web of Science ®Google Scholar
• Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. Antiarrhythmics versus implantable defibrillators I. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576–1583.
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–237.
   PubMed Web of Science ®Google Scholar
• Kim YH, Sosa-Suarez G, Trouton TG, et al. Treatment of ventricular tachycardia by transcatheter radiofrequency ablation in patients with ischemic heart disease. Circulation. 1994;89(3):1094–1102.
   PubMedGoogle Scholar
• Kirchhof P, Calkins H. Catheter ablation in patients with persistent atrial fibrillation. Eur Heart J. 2017;38(1):20–26.
   PubMed Web of Science ®Google Scholar
• Villacastin J, Perez-Castellano N, Moreno J, et al. Left atrial flutter after radiofrequency catheter ablation of focal atrial fibrillation. J Cardiovasc Electrophysiol. 2003;14(4):417–421.
   PubMedGoogle Scholar
• Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348(9019):7–12.
   PubMed Web of Science ®Google Scholar
• Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406–412.
   PubMed Web of Science ®Google Scholar
• Persson R, Earley A, Garlitski AC, et al. Adverse events following implantable cardioverter defibrillator implantation: a systematic review. J Interv Card Electrophysiol. 2014;40(2):191–205.
   PubMed Web of Science ®Google Scholar
• Nattel S, Dobrev D. Innovative therapeutics for atrial fibrillation: imminent breakthroughs or much ado about nothing? J Cardiovasc Pharmacol. 2015;66(5):409–411.
   PubMedGoogle Scholar
• Ishikawa K, Weber T, Hajjar RJ. Human cardiac gene therapy. Circ Res. 2018;123(5):601–613.
   PubMed Web of Science ®Google Scholar
• Lozano-Velasco E, Franco D, Aranega A, et al. Genetics and epigenetics of atrial fibrillation. Int J Mol Sci. 2020;21(16):5717.
   PubMed Web of Science ®Google Scholar
• Hedman M, Muona K, Hedman A, et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther. 2009;16(5):629–634.
   PubMed Web of Science ®Google Scholar
• Favaloro L, Diez M, Mendiz O, et al. High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial. Catheter Cardiovasc Interv. 2013;82(6):899–906.
   PubMed Web of Science ®Google Scholar
• Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res. 2007;73(3):453–462.
   PubMedGoogle Scholar
• Su CH, Wu YJ, Wang HH, et al. Nonviral gene therapy targeting cardiovascular system. Am J Physiol Heart Circ Physiol. 2012;303(6):H629–38.
   PubMedGoogle Scholar
• Chung ES, Miller L, Patel AN, et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized phase II trial. Eur Heart J. 2015;36(33):2228–2238.
   PubMed Web of Science ®Google Scholar
• Hargrave B, Downey H, Strange R Jr., et al. Electroporation-mediated gene transfer directly to the swine heart. Gene Ther. 2013;20(2):151–157.
   PubMedGoogle Scholar
• Trivedi A, Arora R. Gene therapy for the treatment of cardiac arrhythmias: current and emerging applications. J Innov Card Rhythm Manage. 2018;9(12):3440–3445.
   PubMedGoogle Scholar
• Di Pasquale E, Latronico MV, Jotti GS, et al. Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function. Gene Ther. 2012;19(6):642–648.
   PubMedGoogle Scholar
• Levy C, Verhoeyen E, Cosset FL. Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells. Curr Opin Pharmacol. 2015;24:79–85.
   PubMed Web of Science ®Google Scholar
• Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 2010;17(3):295–304.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348(3):255–256.
   PubMed Web of Science ®Google Scholar
• Greener I, Donahue JK. Gene therapy strategies for cardiac electrical dysfunction. J Mol Cell Cardiol. 2011;50(5):759–765.
   PubMed Web of Science ®Google Scholar
• Amit G, Kikuchi K, Greener ID, et al. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. 2010;121(21):2263–2270.
   PubMed Web of Science ®Google Scholar
• Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999;100(5):468–474.
   PubMed Web of Science ®Google Scholar
• Liu Z, Donahue JK. The use of gene therapy for ablation of atrial fibrillation. Arrhythm Electrophysiol Rev. 2014;3(3):139–144.
   PubMedGoogle Scholar
• Hammond HK, Penny WF, Traverse JH, et al. Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol. 2016;1(2):163–171.
   PubMed Web of Science ®Google Scholar
• Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15(2):65–77.
   PubMed Web of Science ®Google Scholar
• Pacak CA, Byrne BJ. AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol Ther. 2011;19(9):1582–1590.
   PubMed Web of Science ®Google Scholar
• Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14(3):316–327.
   PubMed Web of Science ®Google Scholar
• Gao G, Bish LT, Sleeper MM, et al. Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques. Hum Gene Ther. 2011;22(8):979–984.
   PubMed Web of Science ®Google Scholar
• Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387(10024):1178–1186.
   PubMed Web of Science ®Google Scholar
• Kowal J, Arras G, Colombo M, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci USA. 2016;113(8):E968–77.
   PubMed Web of Science ®Google Scholar
• Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262(19):9412–9420.
   PubMed Web of Science ®Google Scholar
• O’Loughlin AJ, Woffindale CA, Wood MJ. Exosomes and the emerging field of exosome-based gene therapy. Curr Gene Ther. 2012;12(4):262–274.
   PubMed Web of Science ®Google Scholar
• Shaihov-Teper O, Ram E, Ballan N, et al. Extracellular vesicles from epicardial fat facilitate atrial fibrillation. Circulation. 2021;143(25):2475–2493.
   PubMed Web of Science ®Google Scholar
• Ailawadi S, Wang X, Gu H, et al. Pathologic function and therapeutic potential of exosomes in cardiovascular disease. Biochim Biophys Acta. 2015;1852(1):1–11.
   PubMed Web of Science ®Google Scholar
• Armstrong JP, Holme MN, Stevens MM. Re-engineering extracellular vesicles as smart nanoscale therapeutics. ACS Nano. 2017;11(1):69–83.
   PubMed Web of Science ®Google Scholar
• Sahoo S, Adamiak M, Mathiyalagan P, et al. Therapeutic and diagnostic translation of extracellular vesicles in cardiovascular diseases: roadmap to the clinic. Circulation. 2021;143(14):1426–1449.
   PubMedGoogle Scholar
• Luther KM, Haar L, McGuinness M, et al. Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells. J Mol Cell Cardiol. 2018;119:125–137.
   PubMed Web of Science ®Google Scholar
• Hellwinkel J, Redzic J, Harland T, et al. Glioma-derived extracellular vesicles selectively suppress immune responses. Neuro Oncol. 2016;18(4):497–506.
   PubMed Web of Science ®Google Scholar
• Kordelas L, Rebmann V, Ludwig A, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28(4):970–973.
   PubMed Web of Science ®Google Scholar
• Liang Y, Xu X, Li X, et al. Chondrocyte-targeted microRNA delivery by engineered exosomes toward a cell-free osteoarthritis therapy. ACS Appl Mater Interfaces. 2020;12(33):36938–36947.
   PubMed Web of Science ®Google Scholar
• Vandergriff A, Huang K, Shen D, et al. Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide. Theranostics. 2018;8(7):1869–1878.
   PubMed Web of Science ®Google Scholar
• Zahid M, Feldman KS, Garcia-Borrero G, et al. Cardiac targeting peptide, a novel cardiac vector: studies in bio-distribution, imaging application, and mechanism of transduction. Biomolecules. 2018;8(4):147.
   Google Scholar
• Zahid M, Phillips BE, Albers SM, et al. Identification of a cardiac specific protein transduction domain by in vivo biopanning using a M13 phage peptide display library in mice. PLoS One. 2010;5(8):e12252.
   PubMed Web of Science ®Google Scholar
• Mentkowski K, Lang J. Exosomes engineered to express a cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo. Sci Rep. 2019;9(1):10041.
   PubMedGoogle Scholar
• Liang Y, Mathiyalagan P, Kohlbrenner E. AAV-containing exosomes as a novel vector to improve AAV-mediated myocardial gene delivery in resistance to neutralizing antibody [abstract]. Circulation. 2017;136:A15439.
   Google Scholar
• Hudry E, Martin C, Gandhi S, et al. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther. 2016;23(11):819.
   PubMedGoogle Scholar
• Maguire C, Balaj L, Sivaraman S, et al. Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther. 2012;20(5):960–971.
   PubMed Web of Science ®Google Scholar
• Gyorgy B, Fitzpatrick Z, Crommentuijn M, et al. Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo. Biomaterials. 2014;35(26):7598–7609.
   PubMed Web of Science ®Google Scholar
• Lau D, Clausen C, Sosunov E, et al. Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study. Circulation. 2009;119(1):19–27.
   PubMed Web of Science ®Google Scholar
• Schneider C, Jaquet K, Malisius R, et al. Attenuation of cardiac remodelling by endocardial injection of erythropoietin: ultrasonic strain-rate imaging in a model of hibernating myocardium. Eur Heart J. 2007;28(4):499–509.
   PubMedGoogle Scholar
• Ishikawa K, Tilemann L, Fish K, et al. Gene delivery methods in cardiac gene therapy. J Gene Med. 2011;13(10):566–572.
   PubMed Web of Science ®Google Scholar
• Katz MG, Fargnoli AS, Pritchette LA, et al. Gene delivery technologies for cardiac applications. Gene Ther. 2012;19(6):659–669.
   PubMed Web of Science ®Google Scholar
• Grossman P, Han Z, Palasis M. Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv. 2002;55(3):392–397.
   PubMed Web of Science ®Google Scholar
• French B, Mazur W, Geske R. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation. 1994;90(5):2414–2424.
   PubMed Web of Science ®Google Scholar
• Trivedi A, Hoffman J, Arora R. Gene therapy for atrial fibrillation - How close to clinical implementation? Int J Cardiol. 2019;296:177–183.
   PubMedGoogle Scholar
• Kikuchi K, McDonald AD, Sasano T, et al. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation. 2005;111(3):264–270.
   PubMedGoogle Scholar
• Nyns ECA, Poelma RH, Volkers L, et al. An automated hybrid bioelectronic system for autogenous restoration of sinus rhythm in atrial fibrillation. Sci Transl Med. 2019;11(481):eaau6447.
   PubMedGoogle Scholar
• Liu Z, Hutt JA, Rajeshkumar B, et al. Preclinical efficacy and safety of KCNH2-G628S gene therapy for postoperative atrial fibrillation. J Thorac Cardiovasc Surg. 2017;154(5):1644–51 e8.
   PubMedGoogle Scholar
• Fromes Y, Salmo A, Wang X, et al. Gene delivery to the myocardium by intrapericardial injection. Gene Ther. 1999;6(4):683–688.
   PubMedGoogle Scholar
• March KL, Woody M, Mehdi K, et al. Efficient in vivo catheter-based pericardial gene transfer mediated by adenoviral vectors. Clin Cardiol. 1999;22(1 Suppl 1):I23–9.
   PubMedGoogle Scholar
• Lamping KG, Rios CD, Chun JA, et al. Intrapericardial administration of adenovirus for gene transfer. Am J Physiol. 1997;272(1 Pt 2):H310–7.
   PubMedGoogle Scholar
• Korpela H, Jarvelainen N, Siimes S, et al. Gene therapy for ischaemic heart disease and heart failure. J Intern Med. 2021;290(3):567–582.
   PubMedGoogle Scholar
• Ding Z, Fach C, Sasse A, et al. A minimally invasive approach for efficient gene delivery to rodent hearts. Gene Ther. 2004;11(3):260–265.
   PubMed Web of Science ®Google Scholar
• Boekstegers P, Kupatt C. Current concepts and applications of coronary venous retroinfusion. Basic Res Cardiol. 2004;99(6):373–381.
   PubMedGoogle Scholar
• Weber C, Neacsu I, Krautz B, et al. Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther. 2014;21(2):131–138.
   PubMed Web of Science ®Google Scholar
• Sasano T, Kikuchi K, McDonald AD, et al. Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol. 2007;42(5):954–961.
   PubMedGoogle Scholar
• Kornej J, Borschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4–20.
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596.
   PubMed Web of Science ®Google Scholar
• Qin D, Mansour MC, Ruskin JN, et al. Atrial fibrillation-mediated cardiomyopathy. Circ Arrhythm Electrophysiol. 2019;12(12):e007809.
   PubMedGoogle Scholar
• Heist EK, Mansour M, Ruskin JN. Rate control in atrial fibrillation: targets, methods, resynchronization considerations. Circulation. 2011;124(24):2746–2755.
   PubMed Web of Science ®Google Scholar
• Li SJ, Sartipy U, Lund LH, et al. Prognostic significance of resting heart rate and use of beta-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry. Circ Heart Fail. 2015;8(5):871–879.
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–1833.
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667–2677.
   PubMed Web of Science ®Google Scholar
• Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–427.
   PubMed Web of Science ®Google Scholar
• Tilz RR, Rillig A, Thum AM, et al. Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol. 2012;60(19):1921–1929.
   PubMed Web of Science ®Google Scholar
• Winkle RA, Mead RH, Engel G, et al. Long-term results of atrial fibrillation ablation: the importance of all initial ablation failures undergoing a repeat ablation. Am Heart J. 2011;162(1):193–200.
   PubMedGoogle Scholar
• Donahue JK, Heldman AW, Fraser H, et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med. 2000;6(12):1395–1398.
   PubMed Web of Science ®Google Scholar
• Bauer A, McDonald AD, Nasir K, et al. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation. 2004;110(19):3115–3120.
   PubMed Web of Science ®Google Scholar
• Murata M, Cingolani E, McDonald AD, et al. Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circ Res. 2004;95(4):398–405.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zheng S, Geng Y, et al. MicroRNA profiling of atrial fibrillation in canines: miR-206 modulates intrinsic cardiac autonomic nerve remodeling by regulating SOD1. PLoS One. 2015;10(3):e0122674.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Finet JE, Takeuchi A, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2012;125(2):216–225.
   PubMed Web of Science ®Google Scholar
• Bikou O, Thomas D, Trappe K, et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res. 2011;92(2):218–225.
   PubMed Web of Science ®Google Scholar
• Trappe K, Thomas D, Bikou O, et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J. 2013;34(2):147–157.
   PubMed Web of Science ®Google Scholar
• Kunamalla A, Ng J, Parini V, et al. Constitutive expression of a dominant-negative TGF-beta type II receptor in the posterior left atrium leads to beneficial remodeling of atrial fibrillation substrate. Circ Res. 2016;119(1):69–82.
   PubMed Web of Science ®Google Scholar
• Clauss S, Bleyer C, Schuttler D, et al. Animal models of arrhythmia: classic electrophysiology to genetically modified large animals. Nat Rev Cardiol. 2019;16(8):457–475.
   PubMedGoogle Scholar
• Takahashi K, Sasano T, Sugiyama K, et al. High-fat diet increases vulnerability to atrial arrhythmia by conduction disturbance via miR-27b. J Mol Cell Cardiol. 2016;90:38–46.
   PubMed Web of Science ®Google Scholar
• Ihara K, Sasano T, Hiraoka Y, et al. A missense mutation in the RSRSP stretch of Rbm20 causes dilated cardiomyopathy and atrial fibrillation in mice. Sci Rep. 2020;10(1):17894.
   PubMedGoogle Scholar
• Desplantez T. Cardiac Cx43, Cx40 and Cx45 co-assembling: involvement of connexins epitopes in formation of hemichannels and Gap junction channels. BMC Cell Biol. 2017;18(Suppl 1):3.
   PubMedGoogle Scholar
• Sasano T, McDonald AD, Kikuchi K, et al. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med. 2006;12(11):1256–1258.
   PubMed Web of Science ®Google Scholar
• Greener ID, Sasano T, Wan X, et al. Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction. J Am Coll Cardiol. 2012;60(12):1103–1110.
   PubMed Web of Science ®Google Scholar
• Motloch LJ, Cacheux M, Ishikawa K, et al. Primary effect of SERCA 2a gene transfer on conduction reserve in chronic myocardial infarction. J Am Heart Assoc. 2018;7(18):e009598.
   PubMedGoogle Scholar
• Kodirov SA, Brunner M, Busconi L, et al. Long-term restitution of 4-aminopyridine-sensitive currents in Kv1DN ventricular myocytes using adeno-associated virus-mediated delivery of Kv1.5. FEBS Lett. 2003;550(1–3):74–78.
   PubMedGoogle Scholar
• Brunner M, Kodirov SA, Mitchell GF, et al. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am J Physiol Heart Circ Physiol. 2003;285(1):H194–203.
   PubMedGoogle Scholar
• Bongianino R, Denegri M, Mazzanti A, et al. Allele-specific silencing of mutant mRNA rescues ultrastructural and arrhythmic phenotype in mice carriers of the R4496C mutation in the ryanodine receptor gene (RYR2). Circ Res. 2017;121(5):525–536.
   PubMed Web of Science ®Google Scholar
• Pan X, Philippen L, Lahiri SK, et al. In vivo Ryr2 Editing corrects catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2018;123(8):953–963.
   PubMedGoogle Scholar
• Bezzerides VJ, Caballero A, Wang S, et al. Gene therapy for catecholaminergic polymorphic ventricular tachycardia by inhibition of Ca(2+)/calmodulin-dependent kinase II. Circulation. 2019;140(5):405–419.
   PubMed Web of Science ®Google Scholar
• Landstrom AP, Dobrev D, Wehrens XHT. Calcium signaling and cardiac arrhythmias. Circ Res. 2017;120(12):1969–1993.
   PubMed Web of Science ®Google Scholar
• Houle TD, Ram ML, Cala SE. Calsequestrin mutant D307H exhibits depressed binding to its protein targets and a depressed response to calcium. Cardiovasc Res. 2004;64(2):227–233.
   PubMedGoogle Scholar
• de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation. 1988;77(3):589–606.
   PubMed Web of Science ®Google Scholar
• Ashikaga H, Sasano T, Dong J. Magnetic resonance-based anatomical analysis of scar-related ventricular tachycardia: implications for catheter ablation. Circ Res. 2007;101(9):939–947.
   PubMedGoogle Scholar
• Song L, Alcalai R, Arad M, et al. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest. 2007;117(7):1814–1823.
   PubMedGoogle Scholar
• Denegri M, Avelino-Cruz JE, Boncompagni S, et al. Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias. Circ Res. 2012;110(5):663–668.
   PubMed Web of Science ®Google Scholar
• Wehrens XH, Lehnart SE, Marks AR. Intracellular calcium release and cardiac disease. Annu Rev Physiol. 2005;67:69–98.
   PubMed Web of Science ®Google Scholar
• De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation. 2015;131(25):2185–2193.
   PubMedGoogle Scholar
• Guo Y, VanDusen NJ, Zhang L, et al. Analysis of cardiac myocyte maturation using CASAAV, a platform for rapid dissection of cardiac myocyte gene function in vivo. Circ Res. 2017;120(12):1874–1888.
   PubMedGoogle Scholar
• Carroll KJ, Makarewich CA, McAnally J, et al. A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Proc Natl Acad Sci USA. 2016;113(2):338–343.
   PubMedGoogle Scholar
• El Refaey M, Xu L, Gao Y, et al. In vivo genome editing restores dystrophin expression and cardiac function in dystrophic mice. Circ Res. 2017;121(8):923–929.
   PubMed Web of Science ®Google Scholar
• Xie C, Zhang Y, Song L, et al. Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome. Cell Res. 2016;26(10):1099–1111.
   PubMedGoogle Scholar
• Dave J, Raad N, Mittal N, et al. Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modeling a European cardiomyopathy with global impact. Cardiovasc Res. 2022. DOI:https://doi.org/10.1093/cvr/cvac021.
   Google Scholar
• Chew WL, Tabebordbar M, Cheng JK, et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods. 2016;13(10):868–874.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Tsunekawa Y, Hernandez-Benitez R, et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature. 2016;540(7631):144–149.
   PubMed Web of Science ®Google Scholar
• Jiang J, Wakimoto H, Seidman JG, et al. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science. 2013;342(6154):111–114.
   PubMed Web of Science ®Google Scholar
• Nattel S. Allele-specific gene silencing: another step in the inexorable advance of gene therapy for cardiac arrhythmia management. Circ Res. 2017;121(5):480–482.
   PubMedGoogle Scholar
• Matsa E, Dixon JE, Medway C, et al. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J. 2014;35(16):1078–1087.
   PubMed Web of Science ®Google Scholar